In a study published in the journal The Linacre Quarterly, Dr. Lynn Keenan and collaborators did a systematic review the literature to determine the risk of objectively confirmed Venous Thrombosis with the use of Hormonal contraceptives in healthy women compared to nonusers.
The authors searched 1962 publications and identified 15 publications that fit the criteria and were included.
The researchers found the following results.
1.Users of oral contraception with levonorgesterol had increased risk of VT by a range of 2.79–4.07.
2. The first-generation oral contraceptives had an increased risk of VT of 3.37–8.7. The second-generation oral contraceptives had an OR range of 2.79–4.07. Most studies of Third-generation oral contraceptives were in the range of 4–9. Of those that separated gestodene from desogestrel, the gestodene range was 5.2–9.1, and the desogestrel was 4.9–9.1. Oral contraceptives with drospirinone had a risk of 6.3 (2.9–13.7).
3. The nonoral forms showed that depot-medroxyprogesterone carried an RR of 3.6 (1.8–7.1).
4. Levonorgestrel intrauterine devices did not increase risk.
5. Etonogestrel/ethinyl estradiol vaginal rings increased the risk of VT by 6.5. Norelgestromin/ethinyl estradiol patches increased risk of VT by 7.9. Etonogestrel subcutaneous implants by 1.4 and depot-medroxyprogesterone by 3.6.
6. The risk of fatal VT was increased in women aged fifteen to twenty-four by 18.8-fold.
The authors of the study concluded “current hormonal contraceptives carry a three- to nine fold risk of VT compared to nonusers. Third-generation contraceptives are about twice the risk of the other generations. Combined HC vaginal rings and transdermal patches carry a six- to eightfold risk. Obesity can double the risk compared to normal weight. Use during the first year carries the greatest risk, especially in women under age thirty, where the risk increases thirteenfold.”
Informed consent is needed to provide women with information on the medical risks of oral contraceptives. Women should be made aware of these risks when choosing family planning. Abstinence or fertility awareness-based methods are licit, safe, and effective options for women.
This entry was posted
on Wednesday, August 4th, 2021 at 6:17 pm and is filed under News & Commentary.
You can follow any responses to this entry through the RSS 2.0 feed.
You can skip to the end and leave a response. Pinging is currently not allowed.
Sexual Wisdom$6.00
Physicians Healed$4.95
Humanae Vitae$2.95
Does The Birth Control Pill Cause Abortions?$4.50
Good News about Sex & Marriage$13.99
Sterilization Reversal - A Generous Act of Love$12.00
Hormonal Contraception and Risk of Venous Thrombosis
The authors searched 1962 publications and identified 15 publications that fit the criteria and were included.
The researchers found the following results.
1.Users of oral contraception with levonorgesterol had increased risk of VT by a range of 2.79–4.07.
2. The first-generation oral contraceptives had an increased risk of VT of 3.37–8.7. The second-generation oral contraceptives had an OR range of 2.79–4.07. Most studies of Third-generation oral contraceptives were in the range of 4–9. Of those that separated gestodene from desogestrel, the gestodene range was 5.2–9.1, and the desogestrel was 4.9–9.1. Oral contraceptives with drospirinone had a risk of 6.3 (2.9–13.7).
3. The nonoral forms showed that depot-medroxyprogesterone carried an RR of 3.6 (1.8–7.1).
4. Levonorgestrel intrauterine devices did not increase risk.
5. Etonogestrel/ethinyl estradiol vaginal rings increased the risk of VT by 6.5. Norelgestromin/ethinyl estradiol patches increased risk of VT by 7.9. Etonogestrel subcutaneous implants by 1.4 and depot-medroxyprogesterone by 3.6.
6. The risk of fatal VT was increased in women aged fifteen to twenty-four by 18.8-fold.
The authors of the study concluded “current hormonal contraceptives carry a three- to nine fold risk of VT compared to nonusers. Third-generation contraceptives are about twice the risk of the other generations. Combined HC vaginal rings and transdermal patches carry a six- to eightfold risk. Obesity can double the risk compared to normal weight. Use during the first year carries the greatest risk, especially in women under age thirty, where the risk increases thirteenfold.”
Informed consent is needed to provide women with information on the medical risks of oral contraceptives. Women should be made aware of these risks when choosing family planning. Abstinence or fertility awareness-based methods are licit, safe, and effective options for women.
This entry was posted on Wednesday, August 4th, 2021 at 6:17 pm and is filed under News & Commentary. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.